CASCADIAN THERAPEUTICS
Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase ... that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.
CASCADIAN THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
1985-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.cascadianrx.com
Total Employee:
51+
Status:
Active
Contact:
206.801.2100
Email Addresses:
[email protected]
Total Funding:
64.9 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Level 3 Communications Adobe Marketing Cloud CSC Global DNS
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-08-11 | Alpine Biosciences | Alpine Biosciences acquired by Cascadian Therapeutics | 27 M USD |
| 2006-10-01 | ProlX Pharmaceuticals Corp. | ProlX Pharmaceuticals Corp. acquired by Cascadian Therapeutics | N/A |
Investors List
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Cascadian Therapeutics
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Cascadian Therapeutics
Ayer Capital Management
Ayer Capital Management investment in Post-IPO Equity - Cascadian Therapeutics
Kingsbrook Partners
Kingsbrook Partners investment in Post-IPO Equity - Cascadian Therapeutics
Cowen Group
Cowen Group investment in Post-IPO Equity - Cascadian Therapeutics
Hartz Mountain Industries
Hartz Mountain Industries investment in Post-IPO Equity - Cascadian Therapeutics
ArmaVir Partners
ArmaVir Partners investment in Post-IPO Equity - Cascadian Therapeutics
Iroquois Capital
Iroquois Capital investment in Post-IPO Equity - Cascadian Therapeutics
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - Cascadian Therapeutics
Downsview Capital
Downsview Capital investment in Post-IPO Equity - Cascadian Therapeutics
